- Update 9.14.22 MPX Vaccines are available NOW. Call your local health department or the Doc Shop (913-362-0220). Who should be vaccinated to reduce the chance of infection or severe disease with Monkeypox? People who may be at higher risk of serious illness and/or who have an identified risk of exposure. Higher risk-
- * People with immunocompromise
- Rheumatoid arthritis, ulcerative colitis or other auto-immune disease
- Undergoing radiation or chemotherapy or on anti-rejection or immune suppressive medicines
- * People with a history or presence of skin conditions
- varicella zoster virus infection
- herpes simplex virus infection
- severe acne
- * Pregnant or breastfeeding women
- Exposure risks-
What are the signs?Monkeypox symptoms are similar to smallpox symptoms, but usually milder, and monkeypox is not as likely to be fatal. Monkeypox is not related to chickenpox, but the rash looks similar.• During the first 5 days a fever, headache, muscle aches, tiredness and swollen lymph nodes may be present. • Usually within 3 days of the fever, the rash begins to appear. The blisters are usually more concentrated on the face and extremities and may be seen on the palms of the hands and soles of the feet.• After-effects may include chronic tiredness, scarring, loss of vision, fogginess, etc.
More severe symptoms may develop in people with risks including HIV or other immune compromise (undergoing radiation, chemotherapy, organ transplant, etc.)
Who is at risk?Monkeypox is transmitted through large droplets and through close skin-to-skin contact.
Cases have been clustered in men who have sex with men in New York, San Franscisco and elsewhere.
How is it prevented?• Avoid skin-to-skin contact with anyone who has a new rash.• Avoid exposure by using masks, handwashing, etc.• Use condoms during sex.• Do not share eating utensils or cups with others. info from CDC and WHO.
Following the recommended prevention steps and getting vaccinated if you were exposed to monkeypox or are at higher risk of being exposed to monkeypox can help protect you and your community. CDC
• Vaccinia Immune Globulin Intravenous (VIGIV)VIGIV is licensed by FDA for the treatment of complications due to vaccinia vaccination. It is unknown whether a person with severe monkeypox infection will benefit from treatment with VIG. However, healthcare providers may consider its use in severe cases.
VIG can be considered for prophylactic use in an exposed person with severe immunodeficiency in T-cell function for which smallpox vaccination following exposure to monkeypox virus is contraindicated.
• Cidofovir (also known as Vistide) is an antiviral medication approved by the FDA for the treatment of cytomegalovirus (CMV) retinitis in patients with Acquired Immunodeficiency Syndrome (AIDS). It has been effective against orthopoxviruses in in vitro and animal studies. Renal toxicity may be an issue.
• Brincidofovir (also known as Tembexa) is an antiviral medication approved by the FDA in 2021 for the treatment of human smallpox disease in adult and pediatric patients, including neonates. It has shown to be effective against orthopoxviruses in in vitro and animal studies. Brincidofovir is not currently available from the SNS.